LONDON (Thomson Financial) - Oxford Biomedica PLC said its partner MolMed has received regulatory approval to start a Phase III trial of TK therapy for high risk acute leukaemia. The start of a Phase III trial of TK therapy triggers an undisclosed milestone payment to Oxford BioMedica, the company said in a statement.
